![](https://library.celltelligence.com/wp-content/uploads/2020/04/Cellectis-Earnings.png)
$0
Cellectis to Deprioritize its Multiple Myeloma Program; All Ongoing Trials to Include Sanofi’s Alemtuzumab as Lymphodepleting Agent; Cellectis’s Q1 2023 Earnings Call Summary
On Friday, May 5, Cellectis held its Q1 2023 earnings call (press release) highlighting the company’s decision to deprioritize the clinical development of UCARTCS1 (allogeneic CS1 CAR-T) in multiple myeloma to focus on the advancement of the rest of its pipeline. Below, Celltelligence provides insight on Cellectis’s decision to stop investing in its MM program, while discussing the implementation of Sanofi’s alemtuzumab (anti-CD52 mAb) across all its trials.